Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Historic Invested Capital for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $10.1 million.

  • Innate Pharma's Invested Capital rose 517.29% to $10.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $95.8 million, marking a year-over-year decrease of 560.04%. This contributed to the annual value of $33.1 million for FY2024, which is 2283.5% down from last year.
  • Per Innate Pharma's latest filing, its Invested Capital stood at $10.1 million for Q2 2025, which was up 517.29% from $33.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Invested Capital registered a high of $50.6 million during Q4 2021, and its lowest value of $2.4 million during Q2 2021.
  • For the 5-year period, Innate Pharma's Invested Capital averaged around $25.6 million, with its median value being $32.9 million (2022).
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 9988.06% in 2021, then surged by 125527.18% in 2022.
  • Innate Pharma's Invested Capital (Quarter) stood at $50.6 million in 2021, then decreased by 14.85% to $43.1 million in 2022, then decreased by 0.43% to $42.9 million in 2023, then decreased by 22.84% to $33.1 million in 2024, then plummeted by 69.47% to $10.1 million in 2025.
  • Its Invested Capital stands at $10.1 million for Q2 2025, versus $33.1 million for Q4 2024 and $9.6 million for Q2 2024.